Thiazolidinediones and bone

Clinical Cases in Mineral and Bone Metabolism

Volumn 4, Issue 2, 2007, Pages 103-107

  Falchetti, Alberto ^a   Masi, Laura ^a   Brandi, Maria Luisa ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Fracture risk; Metabolic bone disorders; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL NUCLEUS RECEPTOR; CIGLITAZONE; GLIBENCLAMIDE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TROGLITAZONE; VITAMIN D;

BONE DEFECT; BONE DENSITY; BONE MARROW; BONE METABOLISM; CLINICAL PRACTICE; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG INDUSTRY; DRUG MECHANISM; FALLING; FEMUR NECK; FRACTURE; HEALTH CARE PERSONNEL; HUMAN; IN VITRO STUDY; INSULIN SENSITIVITY; LIVER TOXICITY; LYMPHOCYTE TRANSFORMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; POSTMENOPAUSE; PRESCRIPTION; RISK FACTOR; SHORT SURVEY;

EID: 35348956383     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (45)

1. Heath H III, Melton LJ III, Chu CP. Diabetes mellitus and risk of skeletal fracture. N Engl J Med. 1980;303(10):567-570.
2. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL. Risk of Fracture in Women with Type 2 Diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404-3410.
3. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in Patients with Diabetes Mellitus. J Bone Miner Res. 2007 May 14; [Epub ahead of print].
4. Bridges MJ, Moochhala SH, Barbour J, Kelly CA. Influence of diabetes on peripheral bone mineral density in men: a controlled study. Acta Diabetol. 2005;42:82-86.
5. Wakasugi M, Wakao R, Tawata M, Gan N, Koizumi K, Onaya T. Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone. 1993;14:29-33.
6. Perez-Castrillon JL, De Luis D, Martin-Escudero JC, Asensio T, del Amo R, Izaola O. Non-insulin-dependent diabetes, bone mineral density, and cardiovascular risk factors. J Diabetes Complications. 2004;18:317-321.
7. Majima T, Komatsu Y, Yamada T, Koike Y, Shigemoto M, Takagi C, Hatanaka I, Nakao K. Decreased bone mineral density at the distal radius, but not at the lumbar spine or the femoral neck, in Japanese type 2 diabetic patients. Osteoporos Int. 2005;16:907-913.
8. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003;33:646-651.
9. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-72.
10. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologie. 2006;49:1711-21.
11. Nathan DM. Thiazolidinediones for Initial Treatment of Type 2 Diabetes? N Engl J Med. 2006;355(23):2477- 2480.
12. Henney JE. From the Food and Drug Administration. JAMA. 1999;282:932.
13. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004;145(1):401-406.
14. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:4312-4319.
15. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004;35:842-849.
16. Luo XH, Guo L-J, Yuan L-Q, Xie H, Zhou HD, Wu XP, Liao EY. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 2005;309:99-109.
17. Soroceanu MA, Miao D, Bai X-Y, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol. 2004; 183(1):203-216.
18. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPAR-gamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int. 2004;75(4):329-337.
19. Jennermann C, Triantafillou J, Cowan D, Pennink B, Connolly K, Morris D. Effects of thiazolidinediones on bone turnover in the rat. J Bone Miner Res. 1995;10:S241. Abstract S361.
20. Tornvig L, Mosekilde L, Justesen J, Falk E, Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int. 2001;69(1):46-50.
21. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung U-i, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H. PPAR-γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113:846-855
22. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005;146:1226-1235.
23. Okazaki R, Miura M, Toriumi M, et al. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocrinol J. 1999;46:795-801.
24. Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, Thiede MA, Marshak DR. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem. 2000;275:14388-93.
25. Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone. 2007 Jan;40(1):149-59. Epub 2006 Sep 28.
26. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
27. Blair HC, Robinson LJ, Zaidi M. Osteoclast signalling pathways. Biochem Biophys Res Commun. 2005;328:728-38.
28. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun. 1999;260:122-6.
29. Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, et al. The effects of C161→T polymorphisms in exon 6 of peroxisome proliferatoractivated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol. 2005;192:1087-93.
30. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab. 2003;21:166-71.
31. Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol. 1993;137(11):1203-1211.
32. Forsen L, Meyer HE, Midthjell K, Edna T-H. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia. 1999;42(8):920-925.
33. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR; Study of Osteoporotic Features Research Group. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86(1):32-38.
34. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24(7):1192-1197.
35. Ottenbacher KJ, Ostir GV, Peek MK, Goodwin JS, Markides KS. Diabetes mellitus as a risk factor for hip fracture in Mexican American older adults. Journals of Gerontology-Series A Biological Sciences and Medical Sciences. 2002;57(10):M648-M653.
36. Ahmed LA, Joakimsen RM, Berntsen GK, Fønnebø V, Schirmer H. Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø study. Osteoporosis Int. 2006;17(4):495-500.
37. De Liefde II, Van Der KliftM, De Laet CEDH, Van Daele PLA, Hofman A, Pols HAP. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporosis Int. 2005;16(12):1713-1720.
38. Holmberg AH, Johnell O, Nilsson PM, Nilsson JA, Berglund G, Akesson K. Risk factors for hip fractures in a middle-aged population: a study of 33,000 men and women. Osteoporosis Int. 2005;16(12):2185-2194.
39. Keegan THM, Kelsey JL, Sidney S, Quesenberry CP Jr. Foot problems as risk factors of fractures. Am J Epidemiol. 2002;155(10):926-931.
40. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
41. Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care. 2006 Jul;29(7):1573-8.
42. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54.
43. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The peroxisome proliferator-activated Receptor-g Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10.
44. Schwartz AV and Sellmeyer DE. Editorial: Thiazolidinediones: New Evidence of Bone Loss. J Clin Endocrinol Metab. 2007;92(4):1232-4.
45. Kuiper JW, van Kuijk C, Grashuis JL, Ederveen AG, Schutte HE. Accuracy and the influence of marrow fat on quantitative CT and dual-energy X-ray absorptiometry measurements of the femoral neck in vitro. Osteoporosis Int. 1996;6:25-30.